Syndax Announces Additional Positive Data for Revuforj® (revumenib) from AUGMENT-101 Trial in Relapsed or Refractory mNPM1 AML and BEAT AML Frontline Combination TrialPRNewsWire • Monday
Syndax Presents Positive Revuforj® (revumenib) Data in Acute Leukemias from Multiple Trials, Including the SAVE Combination and AUGMENT-101 Trials, at 66th ASH Annual MeetingPRNewsWire • 12/07/24
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)PRNewsWire • 12/03/24
Syndax Announces FDA Approval of Revuforj® (revumenib), the First and Only Menin Inhibitor to Treat Adult and Pediatric Patients with Relapsed or Refractory Acute Leukemia with a KMT2A TranslocationPRNewsWire • 11/15/24
Syndax Announces Positive Pivotal Topline Results from Relapsed or Refractory mNPM1 AML Cohort in AUGMENT-101 Trial of RevumenibPRNewsWire • 11/12/24
Syndax Pharmaceuticals (SNDX) Reports Q3 Loss, Tops Revenue EstimatesZacks Investment Research • 11/05/24
Syndax Reports Third Quarter 2024 Financial Results and Provides Business UpdatePRNewsWire • 11/05/24
Syndax Announces Revumenib Abstracts to Be Presented at the 66th ASH Annual MeetingPRNewsWire • 11/05/24
Syndax Announces New Data from Secondary Analysis of the Pivotal AGAVE-201 Trial of Niktimvo™ (axatilimab-csfr) in Chronic Graft-Versus-Host Disease to Be Presented at 66th ASH Annual MeetingPRNewsWire • 11/05/24
Syndax Pharmaceuticals and Royalty Pharma Enter into $350 Million Royalty Funding Agreement for Niktimvo™PRNewsWire • 11/04/24
Syndax to Announce Third Quarter 2024 Financial Results and Host Conference Call and Webcast on November 5, 2024PRNewsWire • 10/29/24
Incyte and Syndax Announce New England Journal of Medicine Publication of Data from Pivotal AGAVE-201 Trial of Niktimvo™ (axatilimab-csfr) in Chronic Graft-Versus-Host DiseasePRNewsWire • 09/18/24
Foundation Medicine Partners with Syndax to Develop a Companion Diagnostic in Hematology and Support Efforts to Pursue Regulatory Approval for an Assay Based on the FoundationOne®Heme PlatformBusiness Wire • 09/04/24
Syndax Announces Publication in the Journal of Clinical Oncology of Data from the Pivotal AUGMENT-101 Trial of Revumenib in Relapsed/Refractory KMT2Ar Acute LeukemiaPRNewsWire • 08/12/24
Syndax Reports Second Quarter 2024 Financial Results and Provides Clinical and Business UpdatePRNewsWire • 08/01/24
Syndax Announces PDUFA Action Date Extension for Revumenib NDA for Relapsed or Refractory KMT2Ar Acute LeukemiaPRNewsWire • 07/29/24